Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 20,000 Shares

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler purchased 20,000 shares of the stock in a transaction on Monday, January 26th. The shares were bought at an average cost of $11.80 per share, for a total transaction of $236,000.00. Following the transaction, the director directly owned 1,563,210 shares in the company, valued at approximately $18,445,878. The trade was a 1.30% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Biodesix Trading Up 9.8%

NASDAQ BDSX opened at $11.08 on Wednesday. Biodesix, Inc. has a 12 month low of $3.44 and a 12 month high of $21.60. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. The stock has a 50 day moving average of $7.75 and a 200-day moving average of $7.73. The company has a market cap of $88.15 million, a PE ratio of -1.99 and a beta of 0.60.

Biodesix (NASDAQ:BDSX) last issued its earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.44. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. The business had revenue of $21.77 million for the quarter, compared to the consensus estimate of $20.98 million. On average, equities research analysts anticipate that Biodesix, Inc. will post -0.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on BDSX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodesix in a research note on Monday, December 22nd. Wall Street Zen raised shares of Biodesix from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Biodesix currently has a consensus rating of “Moderate Buy” and an average target price of $32.50.

Institutional Trading of Biodesix

A number of institutional investors have recently modified their holdings of BDSX. XTX Topco Ltd increased its position in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after purchasing an additional 102,494 shares during the period. Millennium Management LLC bought a new stake in Biodesix during the third quarter worth about $113,000. Oracle Investment Management Inc. acquired a new stake in Biodesix during the third quarter worth about $113,000. Finally, Aberdeen Group plc bought a new position in Biodesix in the 4th quarter valued at about $1,784,000. 20.96% of the stock is currently owned by institutional investors.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.